BRAVENKnow what's real. Now.
Friday, July 17, 2026
world1 outlet covering thisCalibrating

Regenxbio prices $100m public offering at $9 per share

First publishedJul 17, 11:04 UTC
Last updatedJul 17, 13:52 UTC · 5m ago
11 outletInvesting.com · Company News
Investing.com · Company News5Regenxbio prices $100m public offering at $9 per shareOpen ↗
1 outlets over time — hover a bar for its window & outletslast updated
Regenxbio prices $100m public offering at $9 per share
● Story signals

How strong is this topic?

5.6/10Significanceimpact & urgency
5.0/10Source trustoutlet authority
1Outletsindependent sources

Significance weighs impact, urgency & coverage breadth · Source trust is the outlets' average authority · more outlets means a more confirmed story.

Answer

(NASDAQ:RGNX) announced today the pricing of an underwritten public offering of 10,003,889 shares of common stock at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant, according to a press release statement. The gross proceeds from the offering are expected to be approximately $100.0 million before deducting underwriting discounts, commissions and other offering expenses.

Reported by 1 outlet — Investing.com · Company News. See all sources ↓

(NASDAQ:RGNX) announced today the pricing of an underwritten public offering of 10,003,889 shares of common stock at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant, according to a press release statement. The gross proceeds from the offering are expected to be approximately $100.0 million before deducting underwriting discounts, commissions and other offering expenses. The capital raise comes as the stock has declined nearly 20% over the past week to $11.20, and InvestingPro data shows the company burning through cash with negative free cash flow of $236 million over the last twelve months. The offering is expected to close on Monday, July 20, 2026, subject to customary closing conditions.

Read the full report at Investing.com · Company News ↗

Why it matters

A world story we're tracking; its significance and source trust firm up as more outlets confirm it.

In brief
What's the story?
(NASDAQ:RGNX) announced today the pricing of an underwritten public offering of 10,003,889 shares of common stock at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant, according to a press release statement. The gross proceeds from the offering are expected to be approximately $100.0 million before deducting underwriting discounts, commissions and other offering expenses.
How widely is it covered?
1 outlet, average source rating 5.0/10.
When was it last updated?
5m ago.
Different angles across outlets
Coverage map

How outlets are framing the same story

Here's how each outlet is covering the story — compare their headlines and timing at a glance.

  • Coverage card1 outlet
    1Coverage
    Scouting report

    Regenxbio prices $100m public offering at $9 per share

    Sources1
    TypeCoverage
    Investing.com · Company News
Related in the knowledge graph
organizationInvestingProorganizationJP MorganorganizationMorgan StanleyorganizationNasdaqorganizationRegenxbioorganizationREGENXBIO IncorganizationRGNXorganizationROCKVILLE
Sources (1)
Avg source rating 5.0/10
Processing cluster
A1A2A3B1B2B3
Share this article
X / TwitterLinkedInWhatsApp
Summarize with AI (opens AI chat with article URL · Gemini: prompt copied to clipboard)
GPTPerplexityGeminiClaude